Table 2. Body composition, clinical factors and circulating biomarkers absolute values and change over 11 weeks.
| Baseline Mean | Follow-up Mean | Percent Change (%) | Adjusted Group Difference in Mean Change Over Follow-upa | Interaction | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||
| Usual Care | Walking Group | Usual Care | Walking Group | Usual Care | Walking Group | Mean | 95% CI | P | Pb | |
|
|
|
|
|
|
||||||
| BMI, kg/m2 | 28.0 | 28.1 | 27.7 | 27.7 | -1.1 | -1.4 | -0.08 | (-0.53, 0.36) | 0.70 | 0.32 |
| Waist circumference, cm | 102.0 | 103.8 | 99.9 | 100.6 | -2.0 | -3.0 | -0.87 | (-3.82, 2.08) | 0.55 | 0.38 |
| SBP, mm Hg | 162 | 170 | 163 | 157 | 0.7 | -7.6 | -8.51 | (-21.23, 4.21) | 0.18 | 0.37 |
| DBP, mm Hg | 89 | 93 | 88 | 90 | -1.9 | -3.6 | -0.02 | (-6.32, 6.28) | 0.99 | 0.21 |
| C Reactive Protein, mg/L | 0.9 | 1.1 | 1.5 | 0.7 | 40.5 | -61.0 | -0.97 | (-2.27, 0.33) | 0.14 | 0.07 |
| HDL, mmol/L | 1.4 | 1.5 | 1.4 | 1.6 | -0.3 | 8.6 | 0.14 | (0.01, 0.27) | 0.04 | 0.56 |
| LDL, mmol/L | 3.0 | 2.6 | 2.8 | 2.3 | -5.3 | -10.4 | -0.22 | (-0.47, 0.03) | 0.08 | 0.02 |
| C-peptide, ng/mL | 1.5 | 1.6 | 1.9 | 2.1 | 25.5 | 27.8 | 0.09 | (-0.44, 0.62) | 0.74 | 0.36 |
| Testosterone, nmol/L | 10.8 | 11.5 | 10.7 | 11.6 | -0.7 | 0.6 | 0.21 | (-2.02, 2.44) | 0.85 | 0.46 |
| SHBG, nmol/L, adjusted for testosterone | 27. 5 | 28.3 | 24.5 | 25.6 | -10.7 | -9.4 | 0.59 | (-4.18, 5.36) | 0.80 | 0.32 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SHBG: sex hormone-binding globulin; CI: confidence interval.
a
Between group change based on analysis of covariance adjusted for baseline values.
b
P-value for interaction between intervention group and baseline value on follow-up value.